Literature DB >> 26643343

Visual Hallucinations Associated with High Posaconazole Concentrations in Serum.

Leighanne O Parkes1, Matthew P Cheng2, Donald C Sheppard2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26643343      PMCID： PMC4750663          DOI： 10.1128/AAC.02739-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  12 in total

1.  Posaconazole concentrations in the central nervous system.

Authors:  Maria J G T Rüping; Nadine Albermann; Friedrich Ebinger; Irene Burckhardt; Claudia Beisel; Carsten Müller; Jörg J Vehreschild; Matthias Kochanek; Gerd Fätkenheuer; Christopher Bangard; Andrew J Ullmann; Wolfgang Herr; Karin Kolbe; Michael Hallek; Oliver A Cornely
Journal:  J Antimicrob Chemother       Date:  2008-09-28       Impact factor: 5.790

2.  Phospholipidosis in neurons caused by posaconazole, without evidence for functional neurologic effects.

Authors:  Mark E Cartwright; Janet Petruska; Joseph Arezzo; Doyle Frank; Mona Litwak; Richard E Morrissey; James MacDonald; Thomas E Davis
Journal:  Toxicol Pathol       Date:  2009-12       Impact factor: 1.902

Review 3.  Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.

Authors:  Seyedmojtaba Seyedmousavi; Johan W Mouton; Paul E Verweij; Roger J M Brüggemann
Journal:  Expert Rev Anti Infect Ther       Date:  2013-09       Impact factor: 5.091

4.  Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis.

Authors:  Marisa H Miceli; Anthony J Perissinotti; Carol A Kauffman; Daniel R Couriel
Journal:  Mycoses       Date:  2015-06-23       Impact factor: 4.377

5.  Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies.

Authors:  Aaron Cumpston; Ryan Caddell; Alexandra Shillingburg; Xiaoxiao Lu; Sijin Wen; Mehdi Hamadani; Michael Craig; Abraham S Kanate
Journal:  Antimicrob Agents Chemother       Date:  2015-05-18       Impact factor: 5.191

Review 6.  Voriconazole: a new triazole antifungal agent.

Authors:  Leonard B Johnson; Carol A Kauffman
Journal:  Clin Infect Dis       Date:  2003-02-10       Impact factor: 9.079

7.  Structural basis of drug binding to CYP46A1, an enzyme that controls cholesterol turnover in the brain.

Authors:  Natalia Mast; Casey Charvet; Irina A Pikuleva; C David Stout
Journal:  J Biol Chem       Date:  2010-07-28       Impact factor: 5.157

8.  Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults.

Authors:  Rachel Courtney; Sudhakar Pai; Mark Laughlin; Josephine Lim; Vijay Batra
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

9.  Antifungal Azoles: Structural Insights into Undesired Tight Binding to Cholesterol-Metabolizing CYP46A1.

Authors:  Natalia Mast; Wenchao Zheng; C David Stout; Irina A Pikuleva
Journal:  Mol Pharmacol       Date:  2013-04-19       Impact factor: 4.436

10.  Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease.

Authors:  Johan Maertens; Oliver A Cornely; Andrew J Ullmann; Werner J Heinz; Gopal Krishna; Hernando Patino; Maria Caceres; Nicholas Kartsonis; Hetty Waskin; Michael N Robertson
Journal:  Antimicrob Agents Chemother       Date:  2014-04-14       Impact factor: 5.191
View more
  6 in total

1.  Treatment by Posaconazole Tablets, Compared to Posaconazole Suspension, Does Not Reduce Variability of Posaconazole Trough Concentrations.

Authors:  Elodie Gautier-Veyret; Léa Bolcato; Matthieu Roustit; Stéphanie Weiss; Julia Tonini; Marie-Pierre Brenier-Pinchart; Muriel Cornet; Anne Thiebaut-Bertrand; Françoise Stanke-Labesque
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

2.  Posaconazole Plasma Concentrations on Days Three to Five Predict Steady-State Levels.

Authors:  Jürgen Prattes; Wiebke Duettmann; Martin Hoenigl
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

3.  Antifungal Prophylaxis with Posaconazole Delayed-Release Tablet and Oral Suspension in a Real-Life Setting: Plasma Levels, Efficacy, and Tolerability.

Authors:  Martin Hoenigl; Robert Krause; David Lenczuk; Wilma Zinke-Cerwenka; Hildegard Greinix; Albert Wölfler; Jürgen Prattes; Ines Zollner-Schwetz; Thomas Valentin; Timothy C Lin; Andreas Meinitzer
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

4.  Current and promising pharmacotherapeutic options for candidiasis.

Authors:  Liliana Scorzoni; Beth Burgwyn Fuchs; Juliana Campos Junqueira; Eleftherios Mylonakis
Journal:  Expert Opin Pharmacother       Date:  2021-02-04       Impact factor: 3.889

Review 5.  Pharmacokinetics and Pharmacodynamics of Posaconazole.

Authors:  Lu Chen; Elke H J Krekels; Paul E Verweij; Jochem B Buil; Catherijne A J Knibbe; Roger J M Brüggemann
Journal:  Drugs       Date:  2020-05       Impact factor: 9.546

Review 6.  The Pharmacology of Visual Hallucinations in Synucleinopathies.

Authors:  Mirella Russo; Claudia Carrarini; Fedele Dono; Marianna Gabriella Rispoli; Martina Di Pietro; Vincenzo Di Stefano; Laura Ferri; Laura Bonanni; Stefano Luca Sensi; Marco Onofrj
Journal:  Front Pharmacol       Date:  2019-12-09       Impact factor: 5.810
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.